Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Phase Of Takeda’s Globalization Plan Calls For Partial Integration Of Millennium

This article was originally published in PharmAsia News

Executive Summary

The next phase of Takeda’s globalization strategy emphasizes organizational house cleaning. Millennium, which had operated as a standalone oncology outpost, will be partially integrated into Takeda R&D but the commitment to oncology in terms of resources and investment remains firm.

Advertisement

Related Content

Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back
Astellas/Medivation Strengthen Case For Xtandi In Advance Of Second Filing
Affymax’s Omontys Recalled After Deaths; Uncertain Future Ahead For Company
Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch
Takeda’s Strategic Run Up To Nycomed
Millennium Poised To Deliver Late-Stage Pipeline: Q&A With Dr. Karen Ferrante
Merck Suspends Enrollment In Phase II Trial Of Vertex Leukemia Drug Due To Heart Signal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC084420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel